Kalaris Therapeutics Appoints Matthew Gall as Chief Financial Officer

PALO ALTO, Calif.—Kalaris Therapeutics, a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for common retinal diseases, announced the expansion of its leadership team with the appointment of Matthew Gall, MBA, as its new chief financial officer (CFO). The appointment comes as Kalaris enrolls patients in its Phase 1b/2 study for treatment-naïve neovascular age-related macular degeneration (nAMD) patients. Gall most recently served as CFO of iTeos Therapeutics, where he was responsible for business development and overall financial operations and strategy, according to the announcement.